Acadia pharmaceuticals announces u.s. fda approval of daybue™ (trofinetide) for the treatment of rett syndrome in adult and pediatric patients two years of age and older

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that the u.s. food and drug administration (fda) has approved daybue™ (trofinetide) for the treatment of rett syndrome in adult and pediatric patients two years of age and older. daybue is the first and only drug approved for the treatment of rett syndrome. "today marks an important milestone for the rett community and acadia.
ACAD Ratings Summary
ACAD Quant Ranking